IOB - Delayed Quote EUR

bioMérieux S.A. (0RUG.IL)

101.75 +2.50 (+2.52%)
At close: 6:07 PM GMT+1

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Alexandre Merieux Exec. Chairman 1.38M -- 1974
Mr. Pierre Boulud Chief Exec. Officer 1.05M -- 1971
Mr. Frederic Beseme Head of CSR 21.99k -- 1956
Mr. Guillaume Bouhours Exec. VP of Purchasing and Information Systems & CFO -- -- 1976
Sylvain Morgeau Investor Relations -- -- --
Ms. Audrey Dauvet Exec. VP of Legal Affairs & Integrity -- -- 1974
Ms. Valerie Leylde Exec. VP of HR, Communications & CSR -- -- --
Mr. François Lacoste Exec. VP of R&D -- -- --
Mr. Mark Miller Exec. VP & Chief Medical Officer -- -- --
Mr. Pierre Charbonnier Exec. VP of Global Quality, Manufacturing & Supply Chain -- -- --

bioMérieux S.A.

376 Chemin De l’Orme
Marcy l'Étoile, 69280
France
33 4 78 87 20 00 https://www.biomerieux.com
Sector: 
Healthcare
Full Time Employees: 
12,557

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Corporate Governance

bioMérieux S.A.’s ISS Governance QualityScore as of October 1, 2023 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jun 06, 2023
    Ex-Dividend Date

Upcoming Events